NASDAQ
PSTX

Poseida Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Poseida Therapeutics Inc Stock Price

Vitals

Today's Low:
$2.19
Today's High:
$2.305
Open Price:
$2.23
52W Low:
$1.54
52W High:
$8.82
Prev. Close:
$2.23
Volume:
325555

Company Statistics

Market Cap.:
$201.63 million
Book Value:
1.557
Revenue TTM:
$156.71 million
Operating Margin TTM:
-18.39%
Gross Profit TTM:
$-22407000
Profit Margin:
-18.64%
Return on Assets TTM:
-7.4%
Return on Equity TTM:
-29.05%

Company Profile

Poseida Therapeutics Inc had its IPO on 2020-07-10 under the ticker symbol PSTX.

The company operates in the Healthcare sector and Biotechnology industry. Poseida Therapeutics Inc has a staff strength of 348 employees.

Stock update

Shares of Poseida Therapeutics Inc opened at $2.23 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.19 - $2.31, and closed at $2.2.

This is a -1.35% slip from the previous day's closing price.

A total volume of 325,555 shares were traded at the close of the day’s session.

In the last one week, shares of Poseida Therapeutics Inc have increased by +3.77%.

Poseida Therapeutics Inc's Key Ratios

Poseida Therapeutics Inc has a market cap of $201.63 million, indicating a price to book ratio of 2.2648 and a price to sales ratio of 3.5246.

In the last 12-months Poseida Therapeutics Inc’s revenue was $156.71 million with a gross profit of $-22407000 and an EBITDA of $-23375000. The EBITDA ratio measures Poseida Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Poseida Therapeutics Inc’s operating margin was -18.39% while its return on assets stood at -7.4% with a return of equity of -29.05%.

In Q2, Poseida Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 641.2%.

Poseida Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.05 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Poseida Therapeutics Inc’s profitability.

Poseida Therapeutics Inc stock is trading at a EV to sales ratio of 1.9881 and a EV to EBITDA ratio of -16.1021. Its price to sales ratio in the trailing 12-months stood at 3.5246.

Poseida Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$281.22 million
Total Liabilities
$49.89 million
Operating Cash Flow
$43.07 million
Capital Expenditure
$1.18 million
Dividend Payout Ratio
0%

Poseida Therapeutics Inc ended 2024 with $281.22 million in total assets and $0 in total liabilities. Its intangible assets were valued at $281.22 million while shareholder equity stood at $135.30 million.

Poseida Therapeutics Inc ended 2024 with $8.46 million in deferred long-term liabilities, $49.89 million in other current liabilities, 9000.00 in common stock, $-537164000.00 in retained earnings and $4.23 million in goodwill. Its cash balance stood at $49.91 million and cash and short-term investments were $214.61 million. The company’s total short-term debt was $5,863,000 while long-term debt stood at $58.40 million.

Poseida Therapeutics Inc’s total current assets stands at $230.20 million while long-term investments were $0 and short-term investments were $164.70 million. Its net receivables were $11.91 million compared to accounts payable of $2.10 million and inventory worth $0.

In 2024, Poseida Therapeutics Inc's operating cash flow was $43.07 million while its capital expenditure stood at $1.18 million.

Comparatively, Poseida Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$2.2
52-Week High
$8.82
52-Week Low
$1.54
Analyst Target Price
$11.8

Poseida Therapeutics Inc stock is currently trading at $2.2 per share. It touched a 52-week high of $8.82 and a 52-week low of $8.82. Analysts tracking the stock have a 12-month average target price of $11.8.

Its 50-day moving average was $2.09 and 200-day moving average was $3.84 The short ratio stood at 2.71 indicating a short percent outstanding of 0%.

Around 2826% of the company’s stock are held by insiders while 5231.8% are held by institutions.

Frequently Asked Questions About Poseida Therapeutics Inc

The stock symbol (also called stock or share ticker) of Poseida Therapeutics Inc is PSTX

The IPO of Poseida Therapeutics Inc took place on 2020-07-10

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$1.06
0
0%
$1.72
-0.09
-4.97%
$0.14
-0.02
-12.5%
Coursera Inc (COUR)
$18.39
0.16
+0.88%
$50.04
-1.01
-1.98%
$12.7
-0.35
-2.68%
$0.02
-0
-2.6%
$0.57
-0
-0.53%
$6.46
-0.34
-5%
$26.7
-0.15
-0.56%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-101, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101, a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria. Poseida Therapeutics, Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

Address

9390 Towne Centre Drive, San Diego, CA, United States, 92121